Last reviewed · How we verify
Fimasartan or Fimasartan/Hydrochlorothiazide
Fimasartan or Fimasartan/Hydrochlorothiazide is a Angiotensin II receptor blocker (ARB) Small molecule drug developed by Boryung Pharmaceutical Co., Ltd. It is currently in Phase 3 development for Hypertension, Hypertension (combination therapy with hydrochlorothiazide).
Fimasartan is an angiotensin II receptor blocker (ARB) that selectively antagonizes the AT1 receptor to reduce vasoconstriction and lower blood pressure.
Fimasartan is an angiotensin II receptor blocker (ARB) that selectively antagonizes the AT1 receptor to reduce vasoconstriction and lower blood pressure. Used for Hypertension, Hypertension (combination therapy with hydrochlorothiazide).
At a glance
| Generic name | Fimasartan or Fimasartan/Hydrochlorothiazide |
|---|---|
| Sponsor | Boryung Pharmaceutical Co., Ltd |
| Drug class | Angiotensin II receptor blocker (ARB) |
| Target | AT1 receptor (Angiotensin II type 1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Fimasartan binds to and blocks the angiotensin II type 1 (AT1) receptor on vascular smooth muscle and other tissues, preventing angiotensin II-mediated vasoconstriction and aldosterone release. This leads to vasodilation and reduced sodium retention, resulting in decreased blood pressure. The hydrochlorothiazide combination formulation adds a thiazide diuretic mechanism to enhance antihypertensive efficacy.
Approved indications
- Hypertension
- Hypertension (combination therapy with hydrochlorothiazide)
Common side effects
- Dizziness
- Headache
- Fatigue
- Hyperkalemia
- Cough
Key clinical trials
- An OS to Evaluate Effectiveness and Safety of Fixed-dose Combinations of FMS/AML or FMS/AML/HCTZ
- Fimasartan in the Senior Subjects (PHASE3)
- Efficacy and Safety of Fimasartan Alone or Combined With HCTZ in Mexican Patients With Essential Hypertension (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fimasartan or Fimasartan/Hydrochlorothiazide CI brief — competitive landscape report
- Fimasartan or Fimasartan/Hydrochlorothiazide updates RSS · CI watch RSS
- Boryung Pharmaceutical Co., Ltd portfolio CI
Frequently asked questions about Fimasartan or Fimasartan/Hydrochlorothiazide
What is Fimasartan or Fimasartan/Hydrochlorothiazide?
How does Fimasartan or Fimasartan/Hydrochlorothiazide work?
What is Fimasartan or Fimasartan/Hydrochlorothiazide used for?
Who makes Fimasartan or Fimasartan/Hydrochlorothiazide?
What drug class is Fimasartan or Fimasartan/Hydrochlorothiazide in?
What development phase is Fimasartan or Fimasartan/Hydrochlorothiazide in?
What are the side effects of Fimasartan or Fimasartan/Hydrochlorothiazide?
What does Fimasartan or Fimasartan/Hydrochlorothiazide target?
Related
- Drug class: All Angiotensin II receptor blocker (ARB) drugs
- Target: All drugs targeting AT1 receptor (Angiotensin II type 1 receptor)
- Manufacturer: Boryung Pharmaceutical Co., Ltd — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension
- Indication: Drugs for Hypertension (combination therapy with hydrochlorothiazide)
- Compare: Fimasartan or Fimasartan/Hydrochlorothiazide vs similar drugs
- Pricing: Fimasartan or Fimasartan/Hydrochlorothiazide cost, discount & access